Widespread commercial evaluation experience spanning multiple therapy areas for biotherapeutics and small molecules; assessments of drug opportunities in specialty care, primary care & those with orphan drug designation; biologic platforms & technologies.
To date, Atebion BDS have experience of conducting evaluations in the following areas
Atebion has conducted work in the following areas:
Immunology & Inflammation: RA, OA, OP, IBD, Orphan diseases; Small molecules and Biotherapeutic approaches
CNS: Neurodegenerative diseases, (MS, PD, AD), Pain, (Acute and chronic), Epilepsy, Migraine, Schizophrenia, Addictive disorders; Orphan diseases
Cardiovascular & Metabolics: Anti-coagulation & thrombosis; Myotonic Dystrophy; Small molecules and biotherapeutics approaches; Orphan diseases
Endocrinology: Diabetes, Adrenal insufficiency; Orphan diseases
Infection & Virology: Community and nosocomial, Gram+ve agents, Gram-ve agents; medical devices; Hepatitis C, Antivirals
Oncology: Solid tumours, haematological tumours, supportive care, CINV; Small molecules, mAbs, Antibody Drug Conjugates; Enabling platform technologies & discovery approaches
Respiratory & Related: Asthma, severe asthma, COPD; Cystic Fibrosis, Bronhiectasis; Lung transplantation; Orphan Diseases; Medical devices
Atebion has provided advice and guidance to BioTechs and research institutions with novel drug discovery tools & platforms, including computational approaches, in silico platforms and dynamic conformational technologies. We have provided direction on drug targets and mechanisms for validation and onward commercialization.
We have provided leadership and assistance in business development activities, introducing clients to suitable license, collaboration and investment partners; driving partnership programmes and investment.
Atebion has provided support, advice and guidance to numerous groups on the development of assets towards key commercial decisions and development milestones. We have assisted research groups in designing drug development programmes for small and large molecules – from discovery to clinic and across a breadth of therapy areas. We have supported groups in the development and commercialization of novel, enabling platforms and diagnostics. We have developed plans across all development stages, from pre-nomination to late clinical. We have worked within mainstream & Orphan indications. Atebion provides Target Product Profiles, market landscaping, competitor analysis and pipeline reviews.
Throughout asset development, Atebion provides business development leadership and support for collaboration or license discussions; investment support and sourcing; advice on target selection and portfolio prioritization.
Atebion has expertise in small and large molecule development. We have provided services across multiple therapy areas for mainstream and Orphan diseases, as well as advising groups with enabling platform technologies.
We have advised companies with novel drug discovery approaches and early-stage compounds, providing drug development pathways by stage, from pre-nomination and lead generation to late clinical development; highlighting key Investment Decision Milestones & inflexion points.
Services have included product profiling, raising investment & Business Development. Within Biotherapeutics, Atebion’s projects have included antibodies, proteins and enzymes, antibody fragments and link proteins, cell line optimization platforms and process development strategies.
Atebion has provided advice, guidance, BD and investment support to companies with technologies relating to biotherapeutics and small molecules, including;
Novel drug discovery approaches
Platforms for drug re-formulation
Analysis, characterization and purification of proteins & mAbs
Drug profile optimization
Conjugation of Antibody Drug Conjugates
We have provided commercial feasibility assessments, investment and BD support and technology development pathways.
Atebion has provided guidance on the development and marketing of smart technologies for improved disease characterisation, tools for fast & accurate patient assessment, point of care diagnostics and novel analytic technologies.
We have provided commercial feasibility assessments, BD guidance and support and investment support.
Atebion has provided support and guidance for a wide range of projects for Orphan diseases, including;
Drug and device development strategies
Regulatory pathway guidance
PreClinical and Clinical development programme plans and costings
We have worked on programmes across multiple therapy areas including Oncology, Immunology, Inflammation, CNS, Ophthalmic, Cardiometabolics, Endocrinology and Respiratory.
We have provided development pathways, commercialization plans & strategies, market landscaping & forecasts, S&M infrastructure and costs.
We have experience of patient sub-populations for adults, paediatrics, infants and pre-terms.
Atebion has worked on drug development and medical device programmes for younger populations, including new-borns, infants and paediatrics.
We have provided development pathways and offered guidance on regulatory pathways and commercialization approaches.
We have provided asset development programmes & market landscaping, commercialization routes, BD and investment support for companies with novel drugs, as well as re-formulations of existing drugs for mainstream and orphan indications.
Atebion regularly provides commercialization feasibility advice for research groups with early stage assets looking to spin-out companies. We also provide ‘preparation for launch’ and launch programmes for companies looking to commercialise late-stage assets, especially within Orphan diseases.
We have worked across multiple therapy areas with small molecules (including with devices) and biotherapeutics.
Atebion has provided programmes and guidance which span multiple Regions, (Europe, US, Japan, Asia Pacific) as well as for individual markets.
We provide sales and marketing infrastructure resource and associated cost estimates, A&P programmes, PhIV development programmes, with full P&L analyses and board presentations as required.
Atebion has provided advice and guidance on compounds and technologies that have potential utility in the growing nutraceutical sector, for BioTech and Major Pharma.
We have provided commercial feasibility reports, development pathways including pricing structures across World Regions, BD support and market forecasts.
Atebion offers considerable expertise in defining plans, trouble-shooting and defining process requirements for biotherapeutics including;
Up- and down-stream process assessments, strategies and optimization
Drug Product strategies
Drug Substance strategies
Small-scale analysis and characterization approaches
Large analytical scale purification tools and programmes
Cell line selection and optimsation
Atebion has provided BD and investment support to companies with early-stage assets for animal health indications, advising on development and regulatory pathways and providing relevant materials for Licensees and investors.